View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 24, 2020updated 25 Mar 2020 11:55am

Covid-19: CEL-SCI to develop therapy; Soligenix works on vaccine

CEL-SCI partnered with the University of Georgia’s Center for Vaccines and Immunology to develop an immunotherapy against Covid-19 infection using its LEAPS peptide approach.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

CEL-SCI partnered with the University of Georgia’s Center for Vaccines and Immunology to develop immunotherapy against Covid-19 infection using its LEAPS peptide approach.

The company began efforts to develop an immunotherapy for the potential treatment of Covid-19 earlier this month.

The partners will conduct pre-clinical studies based on findings from prior testing of LEAPS immunotherapy with the National Institutes for Allergies and Infectious Diseases (NIAID) against H1N1 respiratory virus.

Based on the previous studies, the immunotherapy should reduce or prevent the progression of the novel coronavirus infection, while also expected to block tissue damage from lung inflammation.

The immunotherapy will work by inducing the correct immune responses to the SARS-CoV-2 and does not generate unwanted inflammatory responses that cause lung damage, said the company.

CEL-SCI CEO Geert Kersten said: “We are eager to commence these studies, which if successful, may lead to clinical trials in humans to address the immediate and critical need to treat COVID-19 in the most vulnerable patients.”

Soligenix’s Covid-19 vaccine

Soligenix has collaborated with the University of Hawaiʻi at Mānoa (UH Mānoa) to study Covid-19 vaccine candidates.

The company will assess the use of its heat-stable technology platform against coronaviruses, including SARS-CoV-2. Soligenix is currently using the platform to develop vaccines for other viruses such as Ebola.

In addition to a viral surface glycoprotein, the vaccine platform comprises an adjuvant to boost immunity and a formulation for thermostabilisation.

Soligenix president and CEO Christopher Schaber said: “We believe that creating a vaccine with enhanced stability at elevated temperatures that can obviate the costs and logistical burdens associated with cold chain storage and distribution, has the potential to provide a distinct advantage over other vaccines currently in development and simplifies worldwide distribution.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology